Purple Biotech (PPBT) Shares Outstanding (Weighted Average) (2014 - 2025)
Purple Biotech (PPBT) reported Shares Outstanding (Weighted Average) of $960.1 million for Q4 2025, down 3.99% year-over-year from $1.0 billion in Q4 2024, and down 3.99% on a QoQ basis from $1.0 billion in Q4 2024.
Purple Biotech (PPBT) has 10 years of Shares Outstanding (Weighted Average) data on file, last reported at $960.1 million in Q4 2025.
- Quarterly Shares Outstanding (Weighted Average) fell 3.99% year-over-year to $960.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $960.1 million (down 3.99% YoY) and the FY2025 annual result came in at $960.1 million, down 3.99% from the prior year.
- Shares Outstanding (Weighted Average) retreated to $960.1 million in Q4 2025 per PPBT's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $1.0 billion in Q4 2024 and bottomed at $904054.0 in Q4 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $17.6 million (2021), against an average of $395.9 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) plunged 94.85%; it then soared 90261.58% in 2024.
- Tracing PPBT's Shares Outstanding (Weighted Average) over 5 years: stood at $17.6 million in 2021, then sank by 94.85% to $904054.0 in 2022, then advanced by 22.41% to $1.1 million in 2023, then soared by 90261.58% to $1.0 billion in 2024, then retreated by 3.99% to $960.1 million in 2025.
- Per Business Quant, the three latest PPBT Shares Outstanding (Weighted Average) figures stand at $960.1 million (Q4 2025), $1.0 billion (Q4 2024), and $1.1 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Purple Biotech | 3.58 Bn | 3.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 960.11 Mn |
| Sep 30, 2025 | 4.00 |
| Jun 30, 2025 | 3.00 |
| Dec 31, 2024 | 1.00 Bn |
| Sep 30, 2024 | 23.00 |
| Jun 30, 2024 | 23.00 |
| Dec 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 904,054.00 |
| Dec 31, 2021 | 17.57 Mn |
| Dec 31, 2020 | 11.50 Mn |
| Jun 30, 2020 | 460.00 |
| Dec 31, 2019 | 19.37 Mn |
| Jun 30, 2019 | 140.00 |
| Dec 31, 2018 | 14.21 Mn |
| Jun 30, 2018 | 420.00 |
| Dec 31, 2017 | 9.46 Mn |
| Jun 30, 2017 | 40.00 |
| Dec 31, 2016 | 5.76 Mn |
| Jun 30, 2016 | 40.00 |
| Dec 31, 2015 | 19.25 Mn |
| Sep 30, 2015 | 280.00 |
| Dec 31, 2014 | 1,170.00 |